Navigation Links
Morelli receives AACR fellowship for research in metastatic colorectal cancer
Date:4/15/2013

The University of Texas MD Anderson Cancer Center, accepted the one-year, $50,000 grant at the AACR Annual Meeting 2013 grants reception and dinner. The award is one of six granted to MD Anderson researchers and faculty at the meeting.

The Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow, represents a joint effort to encourage and support a postdoctoral or clinical research fellow conducting translational or clinical research on therapeutic approaches for late stage colorectal cancer. The grant supports a project designed to lead to individualized treatment options for patients.

Colorectal cancer is the fourth common cancer diagnosed in the United States each year. The National Cancer Institute estimates 142,820 new cases of colon or rectal cancer bill be diagnosed in 2013, and 50,830 patients will die of the disease.

Over the last decade, the development of anti-epidermal growth factor receptor monoclonal antibodies, such as cetuximab and panitumumab, has improved the clinical outcomes in metastatic colorectal cancer patients who don't have KRAS mutations. Yet, not all of these select patients obtain clinical benefits, and refinement of the predictive biomarker is necessary, says Scott Kopetz, M.D., Ph.D., associate professor in MD Anderson's Department of Gastrointestinal Medical Oncology.

"A patient's tumor is composed of many variations of always-changing cancer cells," said Kopetz, Morelli's mentor. "Standard methods don't capture the current state of the cancer at the time that treatment is started. With recently developed techniques, the patient's blood can provide an increasingly transparent window into the current inter-workings of the cell, allowing better selection of chemotherapy treatments."

Morelli's project will aim to answer specific clinical research questions relevant to the biology of colorectal cancer, and provide insights that may advance the care of patients in the near future.

"Specifically, we will focus on two critical aspects of tumor biology that are anticipated to have profound clinical outcomes: the recognition that both tumor heterogeneity and the acquired mutations in KRAS and EGFR play a substantial role in determining resistance to chemotherapy," Morelli said.

Lisa Dubow was 42 years old when she was diagnosed with Stage III colorectal cancer, which later recurred. A founder of the Fight Colorectal Cancer, Dubow also worked for the "Lisa Fund," which supports researchers and is dedicated to improving therapies and outcomes for patients with late-stage disease.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
2. Christopher Jayne, M.D., Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
3. Local Female Clinical Research Executive Receives Industry Distinction as an Innovator for Change
4. Tosh Patterson Receives Honors at the 5th Annual Get RADICAL Women’s Conference Featuring Jillian Michaels, Lisa Nichols, Giuliana Rancic
5. Vincent R. Lucente, MD, MBA, Miles Murphy, MD, Nina Bhatia, MD, and Valerie Schissler, MSN, CRNP, Receives InTone Specialist Certification
6. Advanced Mold Diagnostics Receives Angie's List Super Service Award for 4th Straight Year
7. BU student receives 2013 Joanna M. Nicolay Melanoma Foundation scholarship award
8. UC Davis MIND Institute receives prestigious Autism Centers of Excellence Award
9. Citel’s Portico™ TVA™ Receives Updated Validation from BroadSoft
10. Kessler Foundation scientist receives National MS Society grant for predictors of memory decline
11. Port Washington, NY Dentist Dr. Doron Keren of Gold Coast Family Dental Receives 98 Percent Satisfaction Rating from Patient Reviews
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... Connor Sports, through its Connor Cares initiative, ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame ... in all forms and levels of the game, Connor Sports has committed to a ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... development solutions for drugs, biologics, consumer health and global clinical supply services, today ... Korea to support the company’s continued investment and strategic growth plans in the ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... provider of comprehensive treatment for eating disorders, is opening a brand new child ... provide individuals ages 8-17 and their families with even more specialized eating disorder ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
Breaking Medicine Technology: